Literature DB >> 27162622

An atypical presentation of adult-onset Still's disease complicated by pulmonary hypertension and macrophage activation syndrome treated with immunosuppression: a case-based review of the literature.

Mili V Mehta1, Daniel K Manson1, Evelyn M Horn2, Jennifer Haythe3.   

Abstract

Pulmonary arterial hypertension (PAH) is a known complication of rheumatologic diseases, but it is only rarely associated with adult-onset Still's disease (AOSD). We describe the case of a 30-year-old woman who presented in a pulmonary hypertension crisis and was found to have underlying AOSD with PAH and nonspecific interstitial pneumonia (NSIP) with a course complicated by macrophage activation syndrome (MAS). She dramatically improved with steroids, cyclosporine A, and anakinra, with total resolution of the MAS and significant improvement of her pulmonary arterial pressures. While there are only select case reports of AOSD associated with PAH, this is the first reported case of (1) AOSD complicated by both PAH and MAS and (2) AOSD complicated by biopsy-proven NSIP. Clinically, this case highlights the efficacy of immunosuppressive agents in the treatment of PAH and MAS from underlying AOSD and supports their use in this setting.

Entities:  

Keywords:  anakinra; pulmonary arterial hypertension; secondary hemophagocytic lymphohistiocytosis

Year:  2016        PMID: 27162622      PMCID: PMC4860549          DOI: 10.1086/685112

Source DB:  PubMed          Journal:  Pulm Circ        ISSN: 2045-8932            Impact factor:   3.017


  32 in total

1.  Preliminary criteria for classification of adult Still's disease.

Authors:  M Yamaguchi; A Ohta; T Tsunematsu; R Kasukawa; Y Mizushima; H Kashiwagi; S Kashiwazaki; K Tanimoto; Y Matsumoto; T Ota
Journal:  J Rheumatol       Date:  1992-03       Impact factor: 4.666

2.  Pulmonary hypertension in a patient with adult-onset Stills disease.

Authors:  Eisha Mubashir; M Mubashir Ahmed; Samina Hayat; Maureen Heldmann; Seth Mark Berney
Journal:  Clin Rheumatol       Date:  2006-07-27       Impact factor: 2.980

3.  HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.

Authors:  Jan-Inge Henter; Annacarin Horne; Maurizio Aricó; R Maarten Egeler; Alexandra H Filipovich; Shinsaku Imashuku; Stephan Ladisch; Ken McClain; David Webb; Jacek Winiarski; Gritta Janka
Journal:  Pediatr Blood Cancer       Date:  2007-02       Impact factor: 3.167

4.  An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis.

Authors:  Sergio Davì; Alessandro Consolaro; Dinara Guseinova; Angela Pistorio; Nicolino Ruperto; Alberto Martini; Randy Q Cron; Angelo Ravelli
Journal:  J Rheumatol       Date:  2011-02-01       Impact factor: 4.666

5.  Pulmonary arterial hypertension complicating adult-onset Still's disease.

Authors:  Manisha Thakare; Shabina Habibi; Sumeet Agrawal; Gumdal Narsimulu
Journal:  Clin Rheumatol       Date:  2009-08-11       Impact factor: 2.980

Review 6.  Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies.

Authors:  Grant S Schulert; Alexei A Grom
Journal:  Annu Rev Med       Date:  2014-11-05       Impact factor: 13.739

7.  Treatment of pulmonary hypertension in patients with connective tissue disease and interstitial lung disease.

Authors:  Shikha Mittoo; Thomas Jacob; Andrea Craig; Zoheir Bshouty
Journal:  Can Respir J       Date:  2010 Nov-Dec       Impact factor: 2.409

8.  A case of macrophage activation syndrome successfully treated with anakinra.

Authors:  Alison Kelly; Athimalaipet V Ramanan
Journal:  Nat Clin Pract Rheumatol       Date:  2008-09-30

9.  Connective Tissue Disease-associated Interstitial Lung Disease: A review.

Authors:  Markus Gutsche; Glenn D Rosen; Jeffrey J Swigris
Journal:  Curr Respir Care Rep       Date:  2012-09-21

Review 10.  Pulmonary hypertension associated with connective tissue disease.

Authors:  Karen A Fagan; David B Badesch
Journal:  Prog Cardiovasc Dis       Date:  2002 Nov-Dec       Impact factor: 8.194

View more
  8 in total

Review 1.  Strategy and Challenges of Paraclinical Examinations in Adult-Onset Still's Disease.

Authors:  Nicolas Poursac; Itsaso Odriozola; Marie-Elise Truchetet
Journal:  J Clin Med       Date:  2022-04-16       Impact factor: 4.964

2.  Pulmonary arterial hypertension secondary to adult-onset Still's disease: Response to cyclosporine and sildenafil over 15 years of follow-up.

Authors:  Jason Weatherald; Johan Lategan; Doug Helmersen
Journal:  Respir Med Case Rep       Date:  2016-06-20

Review 3.  Adult-Onset Still's Disease: Still a Serious Health Problem (a Case Report and Literature Review).

Authors:  Mojgan Agha-Abbaslou; Ana Maria Bensaci; Oluchi Dike; Mark C Poznansky; Arooj Hyat
Journal:  Am J Case Rep       Date:  2017-02-03

4.  Anakinra in Still's disease: a profile of its use.

Authors:  Katherine A Lyseng-Williamson
Journal:  Drugs Ther Perspect       Date:  2018-10-31

Review 5.  Mechanisms, biomarkers and targets for adult-onset Still's disease.

Authors:  Eugen Feist; Stéphane Mitrovic; Bruno Fautrel
Journal:  Nat Rev Rheumatol       Date:  2018-10       Impact factor: 20.543

6.  Macrophage activation syndrome and pulmonary arterial hypertension in a patient with adult-onset Still disease: A case report.

Authors:  Furong Zeng; Guangtong Deng; Hui Luo; Xiaoxia Zuo; Yanli Xie
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

7.  Adult-onset Still's disease evolving with multiple organ failure and death: A case report and review of the literature.

Authors:  Zhong-Bin Han; Ju Wu; Jing Liu; He-Ming Li; Kai Guo; Tong Sun
Journal:  World J Clin Cases       Date:  2021-02-06       Impact factor: 1.337

8.  Management of adult-onset Still's disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts.

Authors:  Serena Colafrancesco; Maria Manara; Alessandra Bortoluzzi; Teodora Serban; Gerolamo Bianchi; Luca Cantarini; Francesco Ciccia; Lorenzo Dagna; Marcello Govoni; Carlomaurizio Montecucco; Roberta Priori; Angelo Ravelli; Paolo Sfriso; Luigi Sinigaglia
Journal:  Arthritis Res Ther       Date:  2019-12-11       Impact factor: 5.156

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.